| General |
RITA is well tolerated in mice after intraperitoneal administration, with no observable weight loss at doses up to 10 mg/kg during 1 month. After five injections of 0.1 mg/kg of RITA, the growth of the HCT116 tumors is suppressed by 40%, without apparent effects on the HCT116 TP53-/- tumors. At a dose of 1 or 10 mg/kg, RITA shows strong antitumor activity. |
| Animal model |
SCID mice carrying HCT116 and HCT116 TP53-/- xenografts |
| Formulation |
Phosphate buffered saline |
| Dosages |
0.1 mg/kg, 1 mg/kg or 10 mg/kg |
| Administration |
i.p or i.v. |
| References |
[1] Issaeva N, et al. Nat Med. 2004, 10(12), 1321-1328. |
m.cnreagent.com
